Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced ...

A 32-year-old man developed gastroparesis after taking tirzepatide for weight loss, which isn't approved in India. Doctors ...

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial of its experimental drug CagriSema — a combination of semaglutide and a ...

Palatin Technologies has completed its Phase II study, BMT-801, evaluating the joint administration of melanocortin 4 receptor (MC4R) bremelanotide with tirzepatide, a glucagon-like peptide-1 ...

Phase 2 obesity co-administration study with MC4R agonist bremelanotide plus GLP-1/GIP dual agonist tirzepatide Database lock completed Topline data readout ...

Glucagon-like peptide 1 receptor agonist-based (GLP-1 RA) medications, including semaglutide and the dual GLP-1 RA/gastric inhibitory polypeptide (GIP) medication tirzepatide, have gained widespread ...

Of these, 20% were GLP-1 drugs alone, with a host of other combinations such as GLP-1/gastric inhibitory peptide (GIP), GLP-1/glucagon, and GLP-1/amylin. IQVIA also found there were 50 other ...

A new study published JAMA Ophthalmology has brought attention to a series of vision problems observed in patients taking ...

Users of weight-loss medications like Ozempic and Tirzepatide are going blind, according to a new study. The study, published in JAMA Opthalmology, reports multiple cases of serious eye complications ...

With today’s sweetener market evolving rapidly, experts highlight how natural sweetener solutions are helping beverage-makers ...